SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 156.82+2.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Beltropolis Boy who wrote (985)5/26/1999 9:03:00 AM
From: William Partmann  Read Replies (1) of 1686
 
BEFORE THE BELL - Biogen rises
NEW YORK, May 26 (Reuters) - Shares in Biogen Inc. rose in pre-opening trade Wednesday after the company said its psoriasis drug Amevive would start the last phase of trials.

Biogen was up at 111 on the Instinet electronic trading system, from a Tuesday close of 107-1/16.

Biogen said Tuesday that Amevive would start Phase III tests following positive results in other studies. Phase III tests are typically the final stage before drugs are submitted to the Food and Drug Administration for marketing approval.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News